Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Sutro Biopharma, Inc. (STRO : NSDQ)
 
 • Company Description   
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.

Number of Employees: 310

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.71 Daily Weekly Monthly
20 Day Moving Average: 1,359,865 shares
Shares Outstanding: 84.46 (millions)
Market Capitalization: $60.30 (millions)
Beta: 1.64
52 Week High: $5.17
52 Week Low: $0.52
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -21.10% -24.52%
12 Week -0.50% -18.83%
Year To Date -61.20% -63.22%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
111 Oyster Point Blvd.
-
South San Francisco,CA 94080
USA
ph: 650-881-6500
fax: -
ewhite@sutrobio.com http://www.sutrobio.com
 
 • General Corporate Information   
Officers
William J. Newell - President; Chief Executive Officer and Director
Edward C. Albini - Chief Financial Officer and Corporate Secretary
Michael Dybbs - Director
John G. Freund - Director
Heidi Hunter - Director

Peer Information
Sutro Biopharma, Inc. (CORR.)
Sutro Biopharma, Inc. (RSPI)
Sutro Biopharma, Inc. (CGXP)
Sutro Biopharma, Inc. (BGEN)
Sutro Biopharma, Inc. (GTBP)
Sutro Biopharma, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 869367102
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 84.46
Most Recent Split Date: (:1)
Beta: 1.64
Market Capitalization: $60.30 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.43 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.91 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 50.00% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 0.92
EPS Growth
vs. Year Ago Period: 4.21%
vs. Previous Quarter: -2.25%
Sales Growth
vs. Year Ago Period: 33.76%
vs. Previous Quarter: 24.28%
ROE
06/30/25 - -
03/31/25 - -347.60
12/31/24 - -224.09
ROA
06/30/25 - -
03/31/25 - -59.46
12/31/24 - -52.55
Current Ratio
06/30/25 - -
03/31/25 - 2.16
12/31/24 - 2.60
Quick Ratio
06/30/25 - -
03/31/25 - 2.16
12/31/24 - 2.60
Operating Margin
06/30/25 - -
03/31/25 - -373.66
12/31/24 - -371.46
Net Margin
06/30/25 - -
03/31/25 - -373.66
12/31/24 - -371.46
Pre-Tax Margin
06/30/25 - -
03/31/25 - -370.06
12/31/24 - -362.81
Book Value
06/30/25 - -
03/31/25 - -0.31
12/31/24 - 0.54
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©